A preliminary report found increased IL‐17A expression in both lesional and nonlesional skin of CSU and significant improvement of the weekly urticaria activity score, but also in the severity and frequency of AE in all eight patients treated off‐label with secukinumab [62]. The gene discussed is IL17A; the disease is urticaria.